Did you know?

December 15, 2023 at 3:06 AM · 4 min read. In a notable insider transaction, CFO Michael Secora of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) sold 50,000 shares of the company's stock on ...Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing. The transaction was executed at ...After announcing that it would get a $50 million investment from NVIDIA ( NVDA 0.27%) on July 12, Recursion Pharmaceuticals ( RXRX 8.83%) saw its stock blast off, rising 87% over the following two ...Market Activity. Funds + ETFs. News + Insights. P/E & PEG Ratios. Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm ... Jan 4, 2024 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... Shares of NASDAQ:RXRX opened at $10.23 on Friday. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.54 and a 52 week high of $16.75. The firm’s 50 day moving average is $9.27 and its two ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Find the latest on short interest for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past yearRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...That means RXRX is a top biotech stock capturing the overall trend rather than betting the farm on a single drug or therapeutic. And major players are taking note. Nvidia (NASDAQ: NVDA) is betting ...The budgetary allocation to AI and machine learning in healthcare is expected to reach 10.5% in 2024, up from 5.5% in 2022, Morgan Stanley says. Read more here.

An analysis of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stock in terms of its daily trading volume indicates that the 3-month average is 4.10 million. However, this figure increases on the past 10-day timeline to an average of 4.76 million. Current records show that the company has 183.21M in outstanding shares.Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Recursion Pharmaceuticals ( RXRX -2.00%) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key ...Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company’s equity securities).Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...

2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which ...Jan 19, 2024 · Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements. Recurson Pharmaceuticals (NASDAQ:RXRX) – Purchased 219,586 shares through ARK Genomic Revolution ETF (BATS:ARKG). Ginkgo Bioworks Holdings Inc (NASDAQ:DNA) – Purchased a combined total of ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. 18 hours ago · Investment analysts at TD Cowen started coverage . Possible cause: Jul 17, 2023 · Clinical-stage biotechnology company Recursion Pharmaceuticals Inc.